Journal ArticleDOI
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Hans Ibsen,Kristian Wachtell,Michael H. Olsen,Knut Borch-Johnsen,Lars H Lindholm,Carl Erik Mogensen,Björn Dahlöf,Richard B. Devereux,Ulf de Faire,Frej Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Ole Lederballe-Pedersen,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Ying Wan +16 more
TLDR
Baseline albuminuria is a powerful risk factor for CV events and one-fifth of the difference in favor of losartan on the primary CEP was explained by the greater reduction inalbuminuria onLosartan.Abstract:
ObjectivesTo examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versuread more
Citations
More filters
Journal ArticleDOI
Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Losartan Intervention for Endpoint Reduction in Hypertension Study
Hans Ibsen,Michael H. Olsen,Kristian Wachtell,Knut Borch-Johnsen,Lars H Lindholm,Carl Erik Mogensen,Björn Dahlöf,Richard B. Devereux,Ulf de Faire,F Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Ole Lederballe-Pedersen,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Ying Wan +16 more
TL;DR: Monitoring of albuminuria should be an integrated part of the management of hypertension if it is not decreased by the patient’s current antihypertensive and other treatment, and further intervention directed toward blood pressure control and other modifiable risks should be considered.
Journal ArticleDOI
Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms
TL;DR: At present, the most likely possibility is that a common pathophysiologic process, such as endothelial dysfunction, chronic low-grade inflammation, or increased transvascular leakage of macromolecules, underlies the association between microalbuminuria and cardiovascular disease, but more and prospective studies of these hypotheses are needed.
Journal ArticleDOI
Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research.
TL;DR: The results of these studies not only emphasise the importance of Ang II in the pathophysiology of these diseases but have provided the basis for an evidence-based approach for the use of AIIAs in clinical practice.
Journal ArticleDOI
Microalbuminuria in Type 2 Diabetes and Hypertension: A marker, treatment target, or innocent bystander?
TL;DR: The current literature on the association between albuminuria and adverse cardiovascular and renal outcomes in type 2 diabetes and hypertension is summarized and the evidence that reduction ofalbuminuria leads to improvement in the risk profiles of patients is summarized.
Journal ArticleDOI
Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan: A Double-Blind, Randomized, Prospective Study
Roland E. Schmieder,Arnfried U. Klingbeil,Erwin H. Fleischmann,Roland Veelken,Christian Delles +4 more
TL;DR: The data indicate an additive antiproteinuric effect of ultrahigh dose of the angiotensin receptor blocker candesartan compared with standard dose.
References
More filters
Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TL;DR: Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.
Journal ArticleDOI
Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart Study
TL;DR: The estimation of left ventricular mass by echocardiography offers prognostic information beyond that provided by the evaluation of traditional cardiovascular risk factors, and it is concluded that an increase in left Ventricular mass predicts a higher incidence of clinical events, including death, attributable to cardiovascular disease.
Journal ArticleDOI
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Hans-Henrik Parving,Hendrik Lehnert,Jens Bröchner-Mortensen,Ramon Gomis,Steen Andersen,Peter Arner +5 more
TL;DR: Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria, and serious adverse events were less frequent among the patients treated with the drug.
Journal Article
Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Hans-Henrik Parving,Hendrik Lehnert,Jens Bröchner-Mortensen,Ramon Gomis,Steen Andersen,Peter Arner +5 more
TL;DR: In this article, the authors evaluated the renoprotective effect of an angiotensin II receptor antagonist, irbesartan, in hypertensive type 2 diabetic patients with microalbuminuria.
Journal ArticleDOI
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lars H Lindholm,Hans Ibsen,Björn Dahlöf,Richard B. Devereux,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Krister Kristiansson,Ole Lederballe-Pedersen,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel,Peter Aurup,Jonathan M. Edelman,Steven M. Snapinn +17 more
TL;DR: Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH.